The effect of antisense to NF-κB in an albumin microsphere formulation on the progression of left-ventricular remodeling associated with chronic volume overload in rats

Journal of Drug Targeting

Volumn 22, Issue 9, 2014, Pages 796-804

  Patel, Neil ^a   Addo, Richard T ^b   Ubale, Ruhi ^b   Uddin, Mohammed Nasir ^c   D'Souza, Martin ^d   Jobe, Lynetta ^e  

^a Sullivan University College of Pharmacy   (United States)

^b UNION UNIVERSITY   (United States)

^c WINGATE UNIVERSITY   (United States)

^d MERCER UNIVERSITY   (United States)

^e AUGUSTA UNIVERSITY   (United States)

Author keywords

Albumin microspheres; Antisense; Chronic volume overload; Drug delivery; Heart failure; Myocardial left ventricular remodeling; NF kB; Spray drying; Sustained release

Indexed keywords

ALBUMIN MICROSPHERE; ANTISENSE OLIGONUCLEOTIDE; DRUG VEHICLE; I KAPPA B; TUMOR NECROSIS FACTOR ALPHA; BOVINE SERUM ALBUMIN; DELAYED RELEASE FORMULATION; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICROSPHERE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISENSE THERAPY; ARTICLE; BINDING ASSAY; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE OVERLOAD; HEART LEFT VENTRICLE SIZE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE COMPLIANCE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE REMODELING; IN VIVO STUDY; LEFT VENTRICULAR REMODELING; MALE; MICROENCAPSULATION; MORPHOMETRICS; NONHUMAN; PRESSURE VOLUME CURVE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TARGETING; RAT; SUSTAINED DRUG RELEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DELAYED RELEASE FORMULATION; DISEASE MODEL; DRUG EFFECTS; HEART FAILURE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMALS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; HEART FAILURE; MALE; MICROSPHERES; NF-KAPPA B; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN, BOVINE; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR REMODELING;

EID: 84911498764     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.921927     Document Type: Article

References (51)

1. Bouwmeester T, Bauch A, Ruffner H, et al. A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol 2004;6:97-105.
2. Cogswell JP, Godlevski MM, Wisely GB, et al. NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. J Immunol 1994; 153:712-23.
3. D'Souza MJ, Jin Z, Oettinger CW. Treatment of experimental septic shock with microencapsulated antisense oligomers to NF-kappaB. J Interferon Cytokine Res 2005;25:311-20.
4. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 1990;10:2327-34.
5. Barnes PJ, Adcock IM. NF-κ B: a pivotal role in asthma and a new target for therapy. Trends Pharmacol Sci 1997;18:46-50.
6. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336: 1066-71.
7. Brasier AR. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res 2010; 86:211-18.
8. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 2009;1:a000141 (1-14
9. Tilstra JS, Clauson CL, Niedernhofer LJ, Robbins PD. NF-kappaB in aging and disease. Aging Dis 2011;2:449-65.
10. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol 2003;92:522-8.
11. Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res 2011;108:1122-32.
12. Kawano S, Kubota T, Monden Y, et al. Blockade of NF-kappaB improves cardiac function and survival after myocardial infarction. Am J Physiol Heart Circ Physiol 2006;291:H1337-44.
13. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-72.
14. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000;101: 2981-8.
15. D'Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor kappa B (NF-B): an emerging theme in anti-inflammatory therapies. Mol Interv 2002;2:22-35.
16. Gupta S, Young D, Maitra RK, et al. Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB. J Mol Biol 2008;375:637-49.
17. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010;24:121-32.
18. Cooper SR, Taylor JK, Miraglia LJ, Dean NM. Pharmacology of antisense oligonucleotide inhibitors of protein expression. Pharmacol Ther 1999;82:427-35.
19. Crooke ST. Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1999;1489:31-44.
20. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002;1:347-55.
21. Arnedo A, Espuelas S, Irache JM. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide. Int J Pharm 2002; 244:59-72.
22. Gayakwad SG, Bejugam NK, Akhavein N, et al. Formulation and in vitro characterization of spray-dried antisense oligonucleotide to NF-kappaB encapsulated albumin microspheres. J Microencapsul 2009;26:692-700.
23. Lu W, Sun Q, Wan J, et al. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res 2006;66:11878-87.
24. Mishra V, Mahor S, Rawat A, et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target 2006;14:45-53.
25. Bejugam NK, Gayakwad SG, Uddin AN, D'Souza MJ. Microencapsulation of protein into biodegradable matrix: a smart solution cross-linking technique. J Microencapsul 2013;30:274-82.
26. Siwale RC, Oettinger CW, Addo R, et al. The effect of intracellular delivery of catalase and antisense oligonucleotides to NF-kappaB using albumin microcapsules in the endotoxic shock model. J Drug Target 2009;17:701-9.
27. Akhavein N, Oettinger CW, Gayakwad SG, et al. Treatment of adjuvant arthritis using microencapsulated antisense NF-kappaB oligonucleotides. J Microencapsul 2009;26:223-34.
28. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation 2000;102:IV14-23.
29. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569-82.
30. French BA, Kramer CM. Mechanisms of post-infarct left ventricular remodeling. Drug Discov Today Dis Mech 2007;4:185-96.
31. Mann DL, Spinale FG. Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation 1998;98:1699-702.
32. Brower GL, Henegar JR, Janicki JS. Temporal evaluation of left ventricular remodeling and function in rats with chronic volume overload. Am J Physiol 1996;271:H2071-8.
33. Huang M, Hester RL, Guyton AC. Hemodynamic changes in rats after opening an arteriovenous fistula. Am J Physiol 1992;262: H846-51.
34. Brower GL, Janicki JS. Contribution of ventricular remodeling to pathogenesis of heart failure in rats. Am J Physiol Heart Circ Physiol 2001;280:H674-83.
35. Hall G, Hasday JD, Rogers TB. Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol 2006;41:580-91.
36. Wang X, Ren B, Liu S, et al. Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat. J Appl Physiol 2003;94:752-63.
37. Jobe LJ, Melendez GC, Levick SP, et al. TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload. Am J Physiol Heart Circ Physiol 2009;297:H1462-8.
38. Cosgrove D, Harvey C. Clinical uses of microbubbles in diagnosis and treatment. Med Biol Eng Comput 2009;47:813-26.
39. Dijkmans PA, Juffermans LJ, Musters RJ, et al. Microbubbles and ultrasound: from diagnosis to therapy. Eur J Echocardiogr 2004;5: 245-56.
40. Shohet RV, Chen S, Zhou YT, et al. Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation 2000;101:2554-6.
41. Khan A, Benboubetra M, Sayyed PZ, et al. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J Drug Target 2004;12: 393-404.
42. Oettinger CW, D'souza M J, Akhavein N, et al. Pro-inflammatory cytokine inhibition in the primate using microencapsulated antisense oligomers to NF-kappaB. J Microencapsul 2007;24:337-48.
43. Shastri PN, Ubale RV, D'Souza MJ. Implementation of mixture design for formulation of albumin containing enteric-coated spraydried microparticles. Drug Dev Ind Pharm 2013;39:164-75.
44. Alexis F, Pridgen EM, Langer R, Farokhzad OC. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol 2010;197:55-86.
45. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012;63:185-98.
46. Onai Y, Suzuki J, Maejima Y, et al. Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. Am J Physiol Heart Circ Physiol 2007;292: H530-8.
47. Trescher K, Bernecker O, Fellner B, et al. Adenovirus-mediated overexpression of inhibitor kappa B-alpha attenuates postinfarct remodeling in the rat heart. Eur J Cardiothorac Surg 2004;26: 960-7.
48. Fraccarollo D, Widder JD, Galuppo P, et al. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 2008;118:818-27.
49. Zimmer HG, Heckmann M, Lortet S. Cardiovascular response to triiodothyronine in Sprague-Dawley and spontaneously hypertensive rats. Cardioscience 1993;4:157-62.
50. Frantz S, Ducharme A, Sawyer D, et al. Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. J Mol Cell Cardiol 2003;35: 685-94.
51. Chancey AL, Brower GL, Peterson JT, et al. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 2002;105:1983-8.